Long-term utility of measuring adherence by self-report compared with pharmacy record in a routine clinic setting

被引:64
作者
Fairley, CK
Permana, A
Read, TRH
机构
[1] Univ Melbourne, Melbourne Sexual Hlth Ctr, Melbourne, Vic 3053, Australia
[2] Univ Melbourne, Sch Populat Hlth, Melbourne, Vic 3053, Australia
关键词
adherence; antiretroviral therapy; compliance;
D O I
10.1111/j.1468-1293.2005.00322.x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives To compare long-term adherence to antiretroviral therapy in an HIV service, as measured by self-report and by pharmacy records. To determine the level of adherence by each measure required to suppress viral load in a majority of patients. Methods The percentage of prescribed doses taken was calculated from (a) the number of missed doses in the previous 28 days reported by patients in a questionnaire at each clinic visit, and (b) pharmacy dispensing records. These were compared with each other and with HIV viral load data. Results Mean adherence was 96.2% by pharmacy record over 44 months and 98.6% by self-report over 25 months. The two methods correlated with each other (P<0.001) and the proportion of patients with viral load < 400 HIV-1 RNA copies/mL increased with adherence as measured by self-report (P = 0.001) and pharmacy record (P = 0.004). Fewer than 60% of patients always had viral loads <400 copies/mL if adherence fell below 95% (pharmacy record) or 97% (self-report). Adherence was higher for once-daily than for twice-daily therapy (by pharmacy record: 97.2% vs. 96.0%; P<0.001). Adherence by both measures increased over time. Conclusions Self-reported antiretroviral adherence correlates with pharmacy dispensing records and predicts suppression of viral load at levels >= 97%. It is practical to adopt this into routine HIV clinical care.
引用
收藏
页码:366 / 369
页数:4
相关论文
共 7 条
[1]   Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up [J].
Hogg, RS ;
Heath, K ;
Bangsberg, D ;
Yip, B ;
Press, N ;
O'Shaughnessy, MV ;
Montaner, JSG .
AIDS, 2002, 16 (07) :1051-1058
[2]   Adherence to protease inhibitor therapy and outcomes in patients with HIV infection [J].
Paterson, DL ;
Swindells, S ;
Mohr, J ;
Brester, M ;
Vergis, EN ;
Squier, C ;
Wagener, MM ;
Singh, N .
ANNALS OF INTERNAL MEDICINE, 2000, 133 (01) :21-30
[3]   Adherence to antiretroviral therapy: are we doing enough? [J].
Read, T ;
Mijch, A ;
Fairley, CK .
INTERNAL MEDICINE JOURNAL, 2003, 33 (5-6) :254-256
[4]   Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy - Self-report of the relative importance of multiple attributes of highly active Antiretroviral therapy (HAART) regimens in predicting adherence [J].
Stone, VE ;
Jordan, J ;
Tolson, J ;
Miller, R ;
Pilon, T .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 36 (03) :808-816
[5]  
TROTTA MP, 2002, INT C DRUG THER HIV, P89
[6]  
*US DEP HHS NIH PA, 2004, GUID US ANT AG HIV 1
[7]  
Wilson K J, 2004, Sex Health, V1, P251, DOI 10.1071/SH04020